MA32376B1 - VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME - Google Patents
VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOMEInfo
- Publication number
- MA32376B1 MA32376B1 MA33392A MA33392A MA32376B1 MA 32376 B1 MA32376 B1 MA 32376B1 MA 33392 A MA33392 A MA 33392A MA 33392 A MA33392 A MA 33392A MA 32376 B1 MA32376 B1 MA 32376B1
- Authority
- MA
- Morocco
- Prior art keywords
- leishmaniasis
- immunosuppressant
- fever
- vaccine
- longipalpis
- Prior art date
Links
- 208000004554 Leishmaniasis Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010037660 Pyrexia Diseases 0.000 title 1
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 230000001861 immunosuppressant effect Effects 0.000 title 1
- 239000003018 immunosuppressive agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des vecteurs qui contiennent et expriment in vivo ou in vitro des antigènes salivaires du phlébotome lu. Longipalpis capables de susciter une réponse immunitaire contre la leishmaniose chez l'animal ou l'être humain, des compositions vaccinales comprenant lesdits vecteurs et/ou des polypeptides salivaires de lu. Longipalpis, des procédés de vaccination contre la leishmaniose et des nécessaires à utiliser avec lesdits procédés et compositions.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5163508P | 2008-05-08 | 2008-05-08 | |
US10134508P | 2008-09-30 | 2008-09-30 | |
PCT/US2009/042980 WO2009137577A2 (fr) | 2008-05-08 | 2009-05-06 | Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32376B1 true MA32376B1 (fr) | 2011-06-01 |
Family
ID=41110966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33392A MA32376B1 (fr) | 2008-05-08 | 2010-12-03 | VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME |
Country Status (11)
Country | Link |
---|---|
US (2) | US8603808B2 (fr) |
EP (2) | EP2283035B1 (fr) |
CN (2) | CN103768588A (fr) |
AR (1) | AR071696A1 (fr) |
BR (1) | BRPI0915605B8 (fr) |
ES (1) | ES2760004T3 (fr) |
HK (1) | HK1150616A1 (fr) |
IL (1) | IL209107A (fr) |
MA (1) | MA32376B1 (fr) |
MX (2) | MX348137B (fr) |
WO (1) | WO2009137577A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768588A (zh) * | 2008-05-08 | 2014-05-07 | 梅里亚有限公司 | 使用白蛉唾液免疫原的利什曼原虫疫苗 |
AU2013308623B2 (en) | 2012-08-30 | 2017-03-02 | Merial, Inc. | Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins |
WO2014100073A2 (fr) * | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Vecteurs d'expression utilisables en vue de la production de protéines recombinées dans des cellules de mammifère |
EP3215188A1 (fr) | 2014-11-03 | 2017-09-13 | Merial, Inc. | Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux |
UY37753A (es) | 2017-06-02 | 2018-11-30 | Amgen Inc | Antagonistas de péptido pac1 |
CN113337542A (zh) * | 2021-06-10 | 2021-09-03 | 山西大学 | 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
NZ221790A (en) | 1986-09-12 | 1990-07-26 | Genentech Inc | Method for the continuous production of a heterologous protein in a eukaryotic host cell |
IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
CA2003300A1 (fr) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Cutireaction et trousse pour le depistage du sida |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
US5529780A (en) | 1994-03-30 | 1996-06-25 | Virogenetics Corporation | Nucleotide and amino acid sequences of canine herpesvirus gB and gC |
EP0826063A1 (fr) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Formulations en ampoule unidose de complexes adn/lipides |
EP0803573A1 (fr) | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Construction pour l'expression polycistronique contenant des cytokines pour des vaccins multivalents |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
WO1998000166A1 (fr) | 1996-07-03 | 1998-01-08 | Merial, Inc. | ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
US6017537A (en) | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
EP1203819A3 (fr) | 2000-10-06 | 2002-08-07 | Transgene S.A. | Vecteurs anti-inflammatoires |
IL159463A0 (en) * | 2001-06-19 | 2004-06-01 | Us Gov Health & Human Serv | Anti-arthropod vector vaccines methods of selecting and use thereof |
FR2829498B1 (fr) | 2001-09-11 | 2003-11-28 | Merial Sas | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins |
WO2003062374A2 (fr) | 2001-11-09 | 2003-07-31 | Entremed, Inc. | Genes de synthese de proteines de la malaria et leurs procedes d'utilisation |
WO2004024027A2 (fr) | 2002-06-07 | 2004-03-25 | University Of Florida | Limes endodontiques fabriquees au moyen de verres metalliques en vrac |
WO2004039958A2 (fr) * | 2002-10-29 | 2004-05-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polypeptides de lutzomyia longipalpis et methodes d'utilisation desdits polypeptides |
ES2298829T3 (es) * | 2003-10-24 | 2008-05-16 | Mologen Ag | Agente para el tratamiento de infecciones por leishmania. |
US7582302B2 (en) | 2004-06-04 | 2009-09-01 | Merial Limited | Needle-free administration of FeLV vaccines |
US7512883B2 (en) * | 2004-06-30 | 2009-03-31 | Microsoft Corporation | Portable solution for automatic camera management |
CA2540736A1 (fr) * | 2005-04-08 | 2006-10-08 | Institut Pasteur | Polypeptides de leishmania major et polynucleotides les encodant, applications vaccinales, therapeutiques et diagnostiques de ceux-ci |
EP2086580A2 (fr) * | 2006-11-21 | 2009-08-12 | Merial Limited | Vaccin contre la leishmania canine |
WO2009017689A2 (fr) * | 2007-08-02 | 2009-02-05 | Government Of The U. S. A., As Represented By The Secretary, Dept. Of Health And Human Services | Procédés de détection et de prévention d'une infestation de tiques et d'une transmission de pathogènes |
CN103768588A (zh) * | 2008-05-08 | 2014-05-07 | 梅里亚有限公司 | 使用白蛉唾液免疫原的利什曼原虫疫苗 |
EP2300051B1 (fr) * | 2008-05-21 | 2014-11-12 | Infectious Disease Research Institute | Vaccins polyprotéiques recombinants destinés au traitement et au diagnostic de la leishmaniose |
US8410258B2 (en) * | 2008-05-21 | 2013-04-02 | Infections Disease Research Institute | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis |
WO2010078469A2 (fr) * | 2008-12-31 | 2010-07-08 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Protéines salivaires de phlébotome en tant que nouveaux inhibiteurs du facteur xa et procédés d'utilisation |
WO2010078466A2 (fr) * | 2008-12-31 | 2010-07-08 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Protéines salivaires de phlébotome avec une activité anticomplément et leurs procédés d'utilisation |
US9226958B2 (en) * | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
US8414882B2 (en) * | 2010-11-18 | 2013-04-09 | Merial Limited | Leishmania challenge model |
BR112014001086A2 (pt) * | 2011-07-21 | 2017-02-21 | Consejo Superior De Investig Cientificas/Csic | molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes |
US8916371B2 (en) * | 2012-03-20 | 2014-12-23 | Merial Limited | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof |
-
2009
- 2009-05-06 CN CN201410067819.XA patent/CN103768588A/zh active Pending
- 2009-05-06 BR BRPI0915605-4 patent/BRPI0915605B8/pt active IP Right Grant
- 2009-05-06 ES ES15154516T patent/ES2760004T3/es active Active
- 2009-05-06 WO PCT/US2009/042980 patent/WO2009137577A2/fr active Application Filing
- 2009-05-06 EP EP09743563.0A patent/EP2283035B1/fr active Active
- 2009-05-06 EP EP15154516.7A patent/EP2899203B1/fr active Active
- 2009-05-06 US US12/436,398 patent/US8603808B2/en active Active
- 2009-05-06 MX MX2014013606A patent/MX348137B/es unknown
- 2009-05-06 MX MX2010012069A patent/MX2010012069A/es active IP Right Grant
- 2009-05-06 CN CN2009801236269A patent/CN102066411A/zh active Pending
- 2009-05-08 AR ARP090101680A patent/AR071696A1/es active IP Right Grant
-
2010
- 2010-11-04 IL IL209107A patent/IL209107A/en active IP Right Grant
- 2010-12-03 MA MA33392A patent/MA32376B1/fr unknown
-
2011
- 2011-05-13 HK HK11104707.3A patent/HK1150616A1/zh unknown
-
2013
- 2013-11-01 US US14/069,406 patent/US9228002B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9228002B2 (en) | 2016-01-05 |
EP2283035B1 (fr) | 2015-07-29 |
MX2010012069A (es) | 2010-12-14 |
US8603808B2 (en) | 2013-12-10 |
EP2899203A2 (fr) | 2015-07-29 |
IL209107A (en) | 2017-08-31 |
ES2760004T3 (es) | 2020-05-12 |
BRPI0915605B1 (pt) | 2021-08-24 |
HK1150616A1 (zh) | 2012-01-06 |
BRPI0915605B8 (pt) | 2021-09-08 |
BRPI0915605A2 (pt) | 2016-02-02 |
WO2009137577A3 (fr) | 2010-03-25 |
EP2283035A2 (fr) | 2011-02-16 |
CN103768588A (zh) | 2014-05-07 |
US20090324649A1 (en) | 2009-12-31 |
WO2009137577A2 (fr) | 2009-11-12 |
EP2899203A3 (fr) | 2015-08-05 |
MX348137B (es) | 2017-05-29 |
IL209107A0 (en) | 2011-01-31 |
AR071696A1 (es) | 2010-07-07 |
US20140294875A1 (en) | 2014-10-02 |
EP2899203B1 (fr) | 2019-07-10 |
CN102066411A (zh) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201070329A1 (ru) | Векторы и конструкции для доставки гриппозного антигена | |
MA32376B1 (fr) | VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME | |
WO2005099752A3 (fr) | Vecteurs et constructions d'administration d'antigenes | |
EP2517557A3 (fr) | Modèles animaux et molécules thérapeutiques | |
MY154956A (en) | Chimeric adenoviral vectors | |
EA200702532A1 (ru) | Антитела против мср-1, композиции, способы и применения | |
UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
MX2009006594A (es) | Formulaciones de ph regulado y estables que contienen polipeptidos. | |
EA200701362A1 (ru) | Агонисты glp-1, композиции, способы и применения | |
HN2012001223A (es) | Antagonistas de pcsk 9 | |
TR201000668T1 (tr) | Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati | |
WO2009133378A3 (fr) | Produits et procédés permettant de stimuler une réponse immunitaire | |
SV2006002513A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
WO2006090389A3 (fr) | Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes | |
WO2008103819A3 (fr) | Pseudo-particules virales (vlp) chimériques de la maladie de newcastle | |
MA31014B1 (fr) | Vaccin contre la leishmania canine. | |
CL2011002994A1 (es) | Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal. | |
MA32770B1 (fr) | Anticorps anti-peptides igf-1/e humain modifie | |
EA201100674A1 (ru) | Вакцина против вируса африканской чумы лошадей | |
WO2006117538A3 (fr) | Dosages et leur utilisation | |
EP1858548A4 (fr) | Compositions de peptides de hsp60 et d'antigènes viraux utiles à des fins de vaccination et de diagnostic | |
IN2014CN00547A (fr) |